Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients

Clinics and Research in Hepatology and Gastroenterology

Volumn 40, Issue 5, 2016, Pages 597-604

  Cao, Ying ^a   Bao, Yi ^a,b   Xia, Wei ^c   Wu, Hao ^c   Wei, Feili ^c   Zhang, Yu ^a   Zhang, Renwen ^a   Xu, Xiaoyuan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Department of Gastroenterology   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; BOCEPREVIR; GRAZOPREVIR; PARITAPREVIR; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR; VANIPREVIR;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; NS3 GENE; NS4A GENE; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIRUS GENE; VIRUS LOAD; CHRONIC HEPATITIS C; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; MUTATION;

ADULT; AMINO ACID SUBSTITUTION; COINFECTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEASE INHIBITORS;

EID: 84961783316     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2016.02.004     Document Type: Article

References (45)

1. [1] Shepard, C.W., Finelli, L., Alter, M.J., Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005), 558–567.
2. [2] Qian, H.Z., Vermund, S.H., Kaslow, R.A., et al. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. Aids 20 (2006), 1429–1435.
3. [3] Tian, D., Li, L., Liu, Y., Li, H., Xu, X., Li, J., et al. genotype distributions of HIV-infected individuals in Henan and Guangxi. China. PLoS One, 7, 2012, e50343.
4. [4] Benhamou, Y., Bochet, M., Di Martino, V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30 (1999), 1054–1058.
5. [5] Operskalski, E.A., Kovacs, A., HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 8 (2011), 12–22.
6. [6] Lok, A.S., Gardiner, D.F., Lawitz, E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366 (2012), 216–224.
7. [7] Aghemo, A., De Francesco, R., New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58 (2013), 428–438.
8. [8] Thomas, D.L., Global control of hepatitis C: where challenge meets opportunity. Nat Med 19 (2013), 850–858.
9. [9] Kuntzen, T., Timm, J., Berical, A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48 (2008), 1769–1778.
10. [10] Bacon, B.R., Gordon, S.C., Lawitz, E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1207–1217.
11. [11] Halfon, P., Locarnini, S., Hepatitis C virus resistance to protease inhibitors. J Hepatol 55 (2011), 192–206.
12. [12] Toyota, J., Ozeki, I., Karino, Y., et al. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat 20 (2013), 167–173.
13. [13] Piroth, L., Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. Clin Res Hepatol Gastroenterol 35:Suppl. 2 (2011), S75–S83.
14. [14] Sarrazin, C., Kieffer, T.L., Bartels, D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132 (2007), 1767–1777.
15. [15] Susser, S., Welsch, C., Wang, Y., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50 (2009), 1709–1718.
16. [16] Sullivan, J.C., De Meyer, S., Bartels, D.J., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 57 (2013), 221–229.
17. [17] Lenz, O., Verbinnen, T., Lin, T.I., et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54 (2010), 1878–1887.
18. [18] Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M., et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 62 (2015), 1008–1014.
19. [19] Paolucci, S., Fiorina, L., Piralla, A., et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J, 9, 2012, 245.
20. [20] Romano, K.P., Ali, A., Aydin, C., et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog, 8, 2012, e1002832.
21. [21] Schinazi, R., Halfon, P., Marcellin, P., Asselah, T., HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 34:Suppl. 1 (2014), 69–78.
22. [22] Lontok, E., Harrington, P., Howe, A., et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 62 (2015), 1623–1632.
23. [23] Lopez-Labrador, F.X., Moya, A., Gonzalez-Candelas, F., Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 13 (2008), 481–494.
24. [24] Bai, L., Feng, Z.R., Lu, H.Y., Li, W.G., Yu, M., Xu, X.Y., Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China. Chin Med J (Engl) 122 (2009), 5–9.
25. [25] Peres-da-Silva, A., de Almeida, A.J., Lampe, E., Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol 155 (2010), 807–811.
26. [26] Salvatierra, K., Fareleski, S., Forcada, A., Lopez-Labrador, F.X., Hepatitis C virus resistance to new specifically-targeted antiviral therapy: a public health perspective. World J Virol 2 (2013), 6–15.
27. [27] De Luca, A., Bianco, C., Rossetti, B., Treatment of HCV infection with the novel NS3/4A protease inhibitors. Curr Opin Pharmacol 18 (2014), 9–17.
28. [28] HCV Phenotype Working Group, HCV Drug Development Advisory Group, Clinically relevant HCV drug resistance mutations Fig. and Tables. Ann Forum Collab HIV Res 14 (2012), 1–10.
29. [29] Tong, X., Chase, R., Skelton, A., Chen, T., Wright-Minogue, J., Malcolm, B.A., Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70 (2006), 28–38.
30. [30] Liverton, N.J., Carroll, S.S., Dimuzio, J., et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 54 (2010), 305–311.
31. [31] Phenotype Working Group DDAG, Clinically relevant HCV drug resistance mutations figure and tables (updated). Ann Forum Collab Hiv Res Volume 14 (2012), 1–8.
32. [32] Summa, V., Ludmerer, S.W., McCauley, J.A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56 (2012), 4161–4167.
33. [33] Alter, M.J., Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44 (2006), S6–S9.
34. [34] Zhang, L., Chen, Z., Cao, Y., et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 78 (2004), 13591–13599.
35. [35] Shang, H., Zhong, P., Liu, J., et al. High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China. PLoS One, 5, 2010, e10631.
36. [36] Wu, S., Kanda, T., Nakamoto, S., Imazeki, F., Yokosuka, O., Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol 19 (2013), 8940–8948.
37. [37] Trimoulet, P., Belzunce, C., Faure, M., et al. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med 12 (2011), 506–509.
38. [38] Vicenti, I., Rosi, A., Saladini, F., et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 67 (2012), 984–987.
39. [39] Lisboa-Neto, G., Noble, C.F., Pinho, J.R., et al. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection. Antivir Ther 20 (2015), 281–287.
40. [40] Morsica, G., Bagaglio, S., Uberti-Foppa, C., et al. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 51 (2009), 106–108.
41. [41] Aissa, L.J., Trimoulet, P., Recordon-Pinson, P., et al. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia. J Med Virol 86 (2014), 1350–1359.
42. [42] Sarrazin, C., Lathouwers, E., Peeters, M., et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 116 (2015), 10–16.
43. [43] EASL Recommendations on Treatment of Hepatitis C 2015, J Hepatol 63 (2015), 199–236.
44. [44] Zeuzem, S., Berg, T., Gane, E., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 146 (2014), 430–441.
45. [45] Bartolini, B., Giombini, E., Zaccaro, P., et al. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Res 177 (2013), 205–208.